Patients with prostate cancer seemingly have to face with a dilemma situation. If the cancer left untreated it will continue to spread, while the available hormonal therapies may increase the risk of cataract.
Prostate cancer is the most common type of cancer in men triggered by an increased male hormone testosterone. To overcome it, a therapy usually used to suppress production of testosterone is Androgen Deprivation Therapy (ADT).
There are several ways of ADT, the most popular is in the form of drugs such as Lupron and Zoladex. Another way that is rarely done is through surgery, to remove scrotum testes.
Both have same side effects, which increase the risk of diabetes and obesity. FDA has required to lists the effect of ADT drugs in its packaging.
Since diabetes and obesity associated with the risk of cataract. A study is conducting to prove whether ADT can increase the risk of cataract. From approximately 66,000 prostate cancer patients aged over 66 years. About 50 percent received ADT, majority in drugs form, only a small portion in the form of testicle removal.
From the study, researchers found 111 cases of cataract each year in every 1,000 patients who received ADT. The 9 percent of patients who received ADT is in drugs form and 26 percent of patients are underwent testicle removal.
This study result was published in the journal Annals of Epidemiology.